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Infectious Disease 
Recent Advances Spark Significant Guideline Change: Antiretroviral 
Therapy (ART) at High CD4+ Counts in the Treatment Na"ive Patient 
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Lisa Berni, fifth-year pharmacy student from Dennison OhlO, Kosten Thatcher, fifth-year pharmacy student from Plt!Sburgh Pa .. 
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This knowledge-based act1v1ty 1s targeted for all pharmacists and 
is acceptable for 1.0 hour (0. 1 CEU) of continuing education credit 
This course requires completion of the program evaluation and at 
least a 70 percent grade on the program assessment questions. 
ACPE Universal ACtlVlty Number (UAN): 0048-0000-11-002-H01-P 
Objectives: 
After completion of this program, the reader should be able to 
1. lden!Jfy the pemnent latxlratory values and/or symptomatobgy required 
for ant1retrov1ral therapy m1t1at1on 1n treatment-naive HIV patients. 
2. Descnbe the hm1tat10ns of early versus deferred treatment for HIV 
infection. 
3. List the factors that 1m1t patent adherence to antiretroviral therapy. 
4. Identify !he significant changes made to the newest version of the 
NIH HIV treatment guidelines. 
Abstract 
Human immunodeficiency virus (HIV) targets CD4+ lymphocytes 
a cntical component co proper funcllonmg of the human immune 
system. HIV IS a significant public health concern, having resulted 
mover 27 m1ll10n deaths since 1ts discovery. Currently. several 
different treacment options exist. with combination ant1retrov1ra1 
therapy (ART) at the forefront. Despite the success of ART therapy 
there are number of problems, 1nclud1ng poor patient compliance. 
Due to this, the appropnate time to m1t1ate therapy 1n the treat-
ment na·ive patient 1s under continuous scrutiny. Recently, several 
trials have demonstrated evidence suggesting that initiating ART 
at high CD4+ counts m the treatment na·ive patient 1s beneficial 
m preventing outcomes such as progression to AIDS and death 
due to complicabOns from HIV. This review will discuss two trials 
influenaa1 n the recent change in The National Institute of Health's 
guidelines on therapy for treatment na·ive patients. The trials 
reviewed here are !he North Amencan AIDS Cohort CollaborabOn 
on Research Design (NA-ACCORD) and the Antiretroviral Therapy 
Cohort Collaboraoon (ART-CCI. Despite the success of therapy r 
IS associated with many negall"le side effects and high cost which 
may affect peuem compliance, lead to possible drug resistance and 
result m treatment failure. Along with the new evidence presented 
1n clinical tnals. these factors a so must be considered when 1n1aat-
1ng therapy 1n the treatment naive HIV patient. 
Background 
Human immunodeficiency virus (HIV) infects cells of the immune system 
and progressively leads to the destruction or deterioration of immune 
funcllOn. 1 HIV normally infects humaris by targeting a type of white blood 
cell known as C04+ T lymphocytes, which are nvolved in cell-mediated im-
munity. Viral particles bmd to spec1f1c receptors on the cell surface and fuse 
wltl1 the cell. The wus can then enter the host cell and insert its viral DNA 
into the normal DNA of the host, forcing the newly infected cell to produce 
addlbOnal copies of HIV. These new coptes of HIV can go on to infect other 
cells, leading to a progressive decline m the number and funcbOn of C04+ 
T lymphocytes and attenuation of the immune system. Alter causing a 
significant decline in immune funct1an, HIV can progress mto a roore seri-
ous fonrn known as acquired immune deficiency syndrome (AIDS). AIDS is 
clinically defined as a CD4 +count of less than 200 cells/mm3 or a docu-
mented AIDS-<lefmmg illness. HIV represents one of the world's greatest 
public health challenges, as 1t has claimed more than 27 million lives since 
its discovery. The HIV/AIDS epidemic conllnues to take nearly 2 million 
lives each year.2 More than 33 million peope w:irldwlde , uicluding almost 
1 millK>n m the United States alone, currently liw with HIV/AIDS. HIV can 
be transmitted via a number of different mechanisms mcluding unprotected 
sexual intercourse, contaminated blood transfus10ns, or the sharing of 
conram1nated needles. Infected mothers also can transfer the VJrus to a 
child dunng pregnancy. birth or breastfeeding. Certain pallent populations, 
1nclud1ng men who have sex with men (MSM), Atncan Amencans. and 
Hispamc/Latlno Amencans are at a d1Sproport10nately increased risk for 
contracong the virus. 
As a result of increased patient education on prevenbOn and protection, the 
spread of HIV has decreased 1n recent years.3 However, the total number 
of infected individuals continues to rise as they are idenbfied ea~ier and 
treated with more advanced medication regimens. Anllretrov1ral therapy 
(ART) blocks HIV's activity on CD4+ cells by targehng different stages in 
the HIV lifecycle and decreasing the overall wal load 1n infected individuals. 
HIV antiviral therapy includes a combmaoon of the following drug classes: 
nucleoside reverse transcriptase inhibitors (NRTls), non-nucleoside reverse 
transcriptase inhibitors (NNRTls), protease mh1bitors (Pis). fusK>n inhibi-
tors (Fis), entry inhibitors, and mtegrase strand :ransfer inhibitors (INSTls). 
ART 111volves vanous combinations of the anhVral drug classes. There are 
three preferred reg1meris for treaonent na'1\le pallents 1n the current NIH 
guidelines •The regimens include a 2-NRTI becktx>ne along wltl1 either an 
NNRTI. Pl (nronavir boosted) or INSTI While the efficacy of anbretrov1ral 
therapy 1n slowing the progressK>n of HIV and maintaining higher CD4+ 
counts has long been establ1Shed, there is disagreement about when such 
therapy should be inmated. Over the pest decade, several large-scale chm-
cal tnals have studted the r1Sks and benefits of 1mna11ng ART at higher CD4+ 
counts, resultlng 1n chan9es to the NIH guidelines for anllretrov1ral therapy 
m treatment na·1ve HIV patients. 
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NA-ACCO RD 
The North Amencan AIDS Cohort Collaboration on Research and Design 
(NA-ACCORD) evaluated the rate of death for treatment na·1ve pauents 
who initiated ART therapy within different thresholds of CD4+ counts.5 
Patients in two different CD4 +count ranges, either 351-500 cells/mm3 or 
greater than 500 cells/mm3, were allowed to initiate or defer ART therapy 
a~ a part or U1eir HIV 1Jea1111en1 whe11 e11lering l11e trial. Palienlli who 
initiated ART therapy more than six months alter the start of the trial were 
included in the deferred group. A total of 8 ,362 patients, were included 
in the first analysis, [who contributed 23,977 person-years of follow-up), 
which looked at patients whose baseline CD4+ counts were between 351-
500 cells/mm3• ART therapy was initiated in 25 percent of patients within 
six months, while the remaining 75 percent deferred therapy. The second 
analysis included 9, 155 patients (who contributed 26,439 person-years 
of follow-up) whose CD4+ count was greater than 500 cells/mm3 at the 
beginning of the trial. In this group, 24 percent of patients initiated therapy 
early, and 76 percent deferred for greater than six months. The results 
of this study were significant because they assessed HIV patients with 
CD4+ counts above the guideline recommendation at that bme, which 
did not recommend 1nit1ation of ART unbl CD4+ count decreased to less 
than 350 cells/mm3• Throughout the study, the CD4+ counts and rate of 
death for patients in each group were assessed. A statistically significant 
increase 1n the nsk of death for pabents who deferred therapy was seen 
in both patient groups. The relative risk of death was 69 percent higher 
(P<0.001) for patients who deferred therapy with a CD4+ count of 351-500 
cells/mm3 and 94 percent higher in patients who deferred when their 
CD4+ count was greater than 500 cells/mm3. The large patient popula-
tion and significant duration of observation gave this trial strong external 
validity and allowed death to be used as an endpoint rather than an HIV/ 
AIDS related biomarker. The deferment group in each CD4+ count range 
essentially served as a control for t~e study and allowed for an effective 
analysis of when to initiate ART therapy for patients based on their CD4+ 
count No randomization or blinding of study participants was done in this 
study. However, the use of death as an endpoint limited the risk of bias 
in the results. Relaove nsk ad1J5tments for confounding variable such as 
intravenous drug use and hepatitis C infection were performed , although a 
sensitivity analysis suggested that due to the size of the 01a1, confound1rig 
would have had to have been unnaturally large to affect the results. These 
adjusted refallve-nsk calculations also demonstrated an increased nsk of 
mortality for the deferment group in each of the respective cohorts. 
ART-CC 
The Antiretroviral Therapy Cohort Collaboration (ART-CC) was an analysis 
of 12 cohort studies performed in Europe and North America between 
1995 and 2003.6 The study evaluated ART-na·1ve HIV patients and the 
progression of their disease once ART was initiated. The trial evaluated five 
prognostic variables indicaove of disease progression, including CD4+ cell 
count, HIV-1-RNA level, in)3ction drug use (IOU), age, and clinical AIDS. A 
total of 22,217 patients were included in the cohort database. From the ini-
tiation of ART, 20,379 of the patients were analyzed. Due to a lack of CD4+ 
ce ll counts between months three and nine during the trial, only 16, 167 
were included in the analysis from six months after initiation. For each of 
the vanables, a hazard rat10 was calculated for patients who progressed to 
AIDS before death and patients who died pnor to the progression to AIDS. 
Alter five years, the risk for both endpoints , progression to AIDS followed 
by death or deaUl alone, ranged from 5.6-77 µercent. For exarnµle, palienlS 
who were less than 30 years old, were infected with HIV via some means 
other than IOU, had a CD4+ count of less than 350 oells/mm3 at therapy 
in111aoon and had an HIV-RNA level below 5 log copies/ml possessed only 
a 5.6 percent nsk of death over a five-year period. Patients who were 50 
years old or older, became infected with HIV via IOU, started ART with 
chmcal AIDS and a CD4+ count of less than 25 cells/mm3, had an HIV-
1-RNA level equal to or greater than Slog coptestml and whose disease 
hall proyresseu to AIDS llad a 77 f.JerGenl risk of deaU1 over Uie course of 
the trial. The results of this study demonstrated the signiocance of CD4+ 
cell counts as an indicator of overall survival in HIV patients. The hazard 
ratios (95 percent Cl) ranged from 0.18 for patients with a six-month CD4+ 
count of greater than 350 ce lls/mm3 to 0.75 for those with a six-month 
CD4+ count ranging from 25-49 cells/mm3. This study demonstrated strong 
internal validity due to its large size and adjustrrent in the hazard ratios for 
confounding variables. A limitation of the study was the lack of cause-
specifrc mortality data for patients in each of the respective cohorts. 
Updated Guidelines 
Studies such as the NA-ACCORD analysis and ART-CC mal have contrib-
uted to the increasing evidence in support of early ART therapy rnitiaoon in 
HIV patients. As a result of these and other similar mals, a panel from the 
Department of Health and Human Services made signrficant changes to 
the current ART therapy guidelines with the goal of provld1rig health care 
professionals with recommendations for HIV treatment that reflected the 
find1rigs of the most recent clinical trials. A full vers10n of the new 2010 NIH 
guidelines can be viewed online at www.aidsinfo.nih.gov.4 Among the many 
modifications to the guidelines , the panel made several suggested changes 
to the timing of ART therapy initiation in treatment na·1ve patient Citing evi-
dence of decreased mortality in the NA-ACCORD and ART-CC clinical tri-
als, the panel now recommends initiating therapy in all patients with CD4+ 
counts 500 cells/mm3or less. While the benefits of initiatirig therapy earlier 
were clear1y demonstrated in the above clinical trials, the i:anel remained 
concerned about the long-term impact of side effects on patient adherence 
and the overall success of treatment. As a resul of the NA-ACCORD trial, 
the panel also made a recommendation for patients with CD4+ counts of 
greater than 500 cells/mm3• However, given the lack of supporting evidence 
from other cohorts or randomized clinical tnals, the panel chose 10 classify 
1nrt1aoon of ART therapy in these patients as optional and someth1rig to be 
considered on a case-by-case basis. In all recommendaoons made by the 
panel, they stressed the importance of assessing each individual patient's 
commitment to lifelong ART therapy and adequately explainirig the associ-
ated benefits and risks before initiating therapy. 
Cost 
Patients who choose to begin antiretroviral therapy as a part of their HIV 
treatment are making a lifelong commitment to expensive medications. 
One argument against initiating such high-priced medications earlier in 
the course of HIV progression is that the costs of treatment will be un-
necessarily increased. A 2001 study on the ccst effectiveness of antire t-
rovrral treatment found that patients who initia:ed combination therapy at 
500 cells/mm' could expect to live an average of 9.1 years alter starting 
treatment and would incur a lifetime medical cost of $104, 100.7 Patients 
m the study who chose to defer treatment until therr CD4+ counts fell 
below 200 cells/mm3 were expected to live an add11Jonal 8.51 years at 
a total treatment cost of $98,000. The results also showed an increase 
in the number of opportunistic infections experienced by HIV patients 
who deferreu a11li1e1rovira1 lilerapy. Over U1e course or rnany years of 
treatment, the costs associated with initiating therapy early are relatJvely 
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small compared to the demonstraJed increase in hie expectancy and 
decrease in the nsk for opportunistic rnfectrons. 
Patient Adherence and Adverse Events 
Patient adherence to ART therapy was not addressed rn either study cited by 
the updated treatment guidelines, bJt remains a concern for practitioners and 
patients because 1td1rect1y correlates wrth treatment success. Specifically, 
the most common cause of antiretrovrral treatment failure rn HIV patients IS 
non-adherence Pill burden, timing, tolerability, cost and interactions au limn 
pabent adherence. Zldovudine (AZT) was the first annretroviral medK:ation 
brought to the market m the 1980s. Patients were required to take AZT five 
times darly and experienced a number of debditanng side effects. Although 
newer, more tolerable antiretroviral jrug therapies continue to become avaiJ.. 
able, each current class of antiviral medicaoons has general side effects that 
can affect pabentadherence. NRTls can cause m1tochondnal toxicity includ-
ing lacbc acldos1S, hepabC steatosis and pancreatitis.• NNRTls can produce 
rashes and hepabC dysfunction.'' Pis cause gastrointestinal disturbance 
(nausea, vommng, diarrhea), bleedi~g problems, hepatotox1c1ty and metabolic 
issues 1nclud1ng hypertrprdemra, fat maldistnbution and insulin resrstance. 4• 
Enfuvrrtlde, currently the only Fl on the mar1<et, IS admrnrstered suocutane-
ously and can cause 1npc110n-s1te react10ns, bactenal pneumonia, ir1Somnia, 
nausea and diarrhea u Hepatotoxrc1ty, fever, rash and upper respnatory tract 
mfectJon are oommon side effects seen in maraviroc, an entry inhibitor.'· .. 
Raltegravrr IS an INSTI, the newest ::lass of HIV annretrov1ral drugs, and has 
been associated with an mcrease ui total cholesterol." In addllJOn to toler-
abttny, pdl burden also affects pabent adherence. The availability of combina-
tion annretrov1ral drugs has helped curb some of these adherence issues. 
In add1t10n, drug-drug and drug-food interactions exist and are considered 
in therapy and monitoring. Pharmacists play an important role in screening 
for drug interactions, educating patients on side effects and the importance 
of adherence, as well as screening 'or other health issues and administering 
appropriate rmmumzatJons. Overall, patient adherence must be managed by 
all chnictans, 1nclud1ng phannacists, rn oraer to prevent progress10n of the 
drsease and improve qualny of llfe. 
Drug Resistance 
Annretrov1ral drug res1Stance IS an mportant conslderat10n in the treatment 
of HIV panents because rt can have a signrfrcant rm pact on the success 
of ART therapy and lead to increased mortalrty.11· ' 4 Opponents of early 
antrretrov1ral inltlatJon claim that using these drugs early in the course of 
HIV progress10n can increase the risk for resistance and 11m1t future treat-
ment optrons for panents.15 Resistance to antlretrovrral drugs IS caused by 
mutations in the Viral rarticles that 'esult in different forms of HIV within 
an individual. Some of these variarts of HIV are more resistant to antiret-
rov1ral drugs and can lead to a dee-ease in the effectiveness of treatment 
One of the most uiHuential factors in developing resistance to antiretroviral 
drugs IS poor adherence to medK:ation regimens. Patients who choose to 
inmate therapy and are subsequen:ly poorly adherent expose themselves 
to annretrov1ral drugs but do not fully suppress the replication of the virus. 
The vrrus then can connnue to replcate in the presence of subtherapeubC 
drug concentratlOns, and the rrsk for mutant strains of the virus developing 
is increased The nsk of developing resistance to three ma pr classes of 
antrretrov1ral drugs, NRTls, NNRTls and Pis, has been shown to decrease 
if treatment IS rnltlated at higher CD4+ counts. 16•17 In order to reduce the nsk 
of drug resrstance and maximize the effectiveness of ant1retrov1ral therapy, 
pharmac1Sts and other clinicians mJst stress the importance of medicatlOn 
adherence to panents begrnmng treatment 
Conclusion 
The benefits of rmnaong therapy at CD4+ counts above 350 cells/mm1 
were clearly demonstrated by the NA-ACCORD and ART-CC rnals. and 
the newly refined guidelines renect these new hndrngs. However. treating 
HIV patients with ART therapy does have a number of lim1ta.tJons as well. 
Anoretrovrral drug costs in the United States remain high, and regard-
less of tho CD4' count at which thoy aro m1tiatod, roproscnt a significant 
firiancral burden for patients, insurance companies and government 
programs Many classes of anbretroviral drugs also have serious potential 
side effects that can lead to increased morbidity and decreased patient 
adherence. A ratienrs adherence to their medrcatlOn regimen IS vital to 
slowing the progression of HIV and improVlng h~ expeciancy. Most types 
of anoretrovrral therapy include multiple dlfferen: classes of drugs, and 
the resulnng pll burden can lead to lower rates of adherence m ratients, 
especially those with higher CD4+ counts that may not be experiencing 
an AIDS defining illness. Resistance to ant1retrov1ral drugs, commonly the 
result of poor patient adherence, can hmrt treatment optJorlS for patients 
as they progress through the disease as well. However, despite these and 
other concerns, rt IS important to focus on the consrstently improved patient 
outoomes demonstrated in early 1mt1atron group> from the reviewed clinical 
rnals. Across almost all demographic groups, ~rtJc1pants who rnmated ART 
therapy eartrer in the oourse of the d1Sease were more likely to live longer 
and less likely to progress to clm1:al AIDS. The success of ART m HIV 
ratJents IS dependent on a variety of different factors. and a careful assess-
ment of the rlSks and benefits of treatment must be perfonned for re.bents 
oonsldenng mltlating therapy at any point rn the progress10n of the d1Sease. 
Phannacrsts and other health care professrorials must play an active role in 
d1Scuss1ng the risks and benefits of treatment with patients and assessing 
the readiness to make a lifelong co mm itment to anhretroviral therapy. The 
most recent findings certainly do not signal the end of the debate on ART 
therapy, and HIV treatment will undoubtedly continue to be the focus of 
much d1Scuss10n and research in the future. 
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Assessment Questions 
1. There are currently _______ people in the United 
States living with HIV/AIDS: 
a. 500,000 
b. 1 m1ll1on 
c. 2 m1ll10n 
d. 5 million 
2. All of the following patient populations are at an increased nsk of 
contracting HIV EXCEPT: 
a. Hispanic/Latino Amencans 
b. Men who have sex with men (MSM) 
c. African Americans 
d. All of the above 
3. Which of the following is NOT considered a preferred anti retroviral 
treatment regimen for treatment naive patients 
a. 2-NRTI + 1 Pl (ritonavir roosted) 
b. 2-NRTI + 1 Fl 
c. 2-NRTI + 1 NNRTI 
d. 2-NRTI + 1 INSTI 
4. Which of the followmg CD4+ count values is the minimum at which an 
asymptomatic HIV-positive pacient would not be classified as an AIDS 
patient 
a. 500 ce1Umm3 
b. 200 cells/mm3 
c. 100 cells/mm3 
d. 50 cells/ mm3 
5. The 2010 NIH Guidelines state that antiretroviral therapy should be 
1111tiated in patients with each of the following CD4+ counts EXCEPT 
a. 300 cells/mm3 
b. 350 cells/mm3 
c. 400 cells/mm3 
d. 600 cells/mm3 
6. Results of a study conducted by Schackman et al published in 2001 
suggested that patients initiating ART therapy at 500 cells/mm3 could 
expect to live an additional __ years as a result of treatment 
a. 9.1 years 
b. 7.5 years 
c. 6.3 years 
d. 10.6 years 
7. All of the following are considered to be limitations to patient adher-
ence with antiretroviral therapy EXCEPT: 
a. Pill burden 
b. Cost of treatment 
c. Requires inpatient administration 
d. Side effects 
8. Protease Inhibitors are associated with which of the following side 
effects: 
a. Upper respiratory tract infection 
b. Insulin resistance 
c. Insomnia 
d. Renal failure 
9. Wh1Ch of the fo llowing is considered a role of the pharmacist in im-
proving patient adherence and limiting adverse effects with antiretrovira l 
drugs? 
a. Administering appropriate immunizations 
b. Screening for drug-drug and drug-food mteraclions 
c. Educating patients on common side effects of their med1cat10ns 
d. All of the above 
10. One argument against earlier initiation of ART therapy IS that poor 
patient adherence will lead to an increased nsk of: 
a. Side effects from current medications 
b. Clinically significant bleeding episodes 
c. Liver transplantation 
d. Resistance to antiretrovira l drugs 
To receive continuing education credit for this program, you must 
answer the above questions and fill out the evaluation form. Please visit 
www.onu.edu/pharmacy to enter the required information. Please allow 
two to three weeks for electronic distribution of your continuing educa-
tion certificate , which will be sent to your valid e-mail address in PDF 
format 
Ohio Northern University es accredited t1,' the Accreditation 
Council for Phanracy Education as a provider ol continuing 
pha.nracy education. This program is ehg11:Ae lorcredd until 
Jan. 25, 2014. 
March 2011 Volume two, Issue one THE P HA RMACY AND W ELLNESS R EVIEW 6 
To receive continuing education credit for this program, visit www.01w..et/Jllpltannacy/ CE OR fill out the fonn below 
including your indicated answers to the assessment questions and return to: 
Office of Continuing Education at the Raabe College of Phannacy 
Ohio Northern University 
525 South Main Street 
Ada, Ohio 45810 
Program Title: Recent Advances Sp:uk Significant Guideline Change: Antiretrovii·al Therapy (ART) at high CD4+ Counts in the Treabnent N:iive Patient 
UAN: 0048-0000-11-002-HOl-P CEU's: 0.1 
All infonnation must be printed CLEARLY to ensure accurate record keeping for attendance and the awarding of 
continuing education credit. Certificates will be distributed as a PDF document to a valid Email address. 
NaJDe: 
Add1·ess: 
City: State: Zip: 
Phone: E-mail 
Phannacy License #: State: ONU Alumni? Y 
.. . 
The program objectives were clear. 
The program met the stated goals & objectives; 
Identify the pertinent laboratory values and/or symptomatology required for 
antiretroviral therapy initiation in treatment-naive HIV patients. 
Describe the limitations of early versus defen-ed treatment for HIV infection. 
List the factors that limit patient adherence to antiretroviral therapy. 
Identify tl1e significant changes made to the newest version of the NIH HIV 
treatment guidelines. 
The program met your educational needs. 
Content of the program was interesting. 
Material presented was relevant to my practice. 
Comments/Suggestions for future programs: 
Thank You! 
Answers to Assessment Questions - Please Circle Your Answer 
I.AB CD 
2.A B CD 
3.A B CD 
4.A B CD 
5.A B C D 
6.A B C D 
7.A B C D 
8.A B CD 
9.A B C D 
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10.A B CD 
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